314 assets in Malignant Pancreatic Neoplasm

Therapeutic assets addressing Malignant Pancreatic Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ketorolac Malignant Pancreatic Neoplasm	Andrew Hendifar, MD	Early P1	C (36)
Nisevokitug Malignant Pancreatic Neoplasm	Kimberly Perez, MD	P2	C (35)
Bazedoxifene Malignant Pancreatic Neoplasm	Hôpital Fribourgeois	N/A	D (30)
FAZA Malignant Pancreatic Neoplasm	University Health Network, Toronto	N/A	D (30)
Lidocaine Malignant Pancreatic Neoplasm	Alexandria University	N/A	D (30)
Soluble Fluorescein Malignant Pancreatic Neoplasm	Mayo Clinic	N/A	D (30)
cp-383 Malignant Pancreatic Neoplasm	Tasca Therapeutics	P1/2	NR ()
hr070803 Malignant Pancreatic Neoplasm	Jiangsu HengRui Medicine Co., Ltd.	P3	NR ()
Hrs-4642 Malignant Pancreatic Neoplasm	The First Affiliated Hospital with Nanjing Medical University	P2	NR ()
Irinotecan Hydrochloride Liposome Malignant Pancreatic Neoplasm	Jiangsu HengRui Medicine Co., Ltd.	P3	NR ()
MIL-97 Malignant Pancreatic Neoplasm	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	NR ()
Sapdm275 Tumor Vaccine Malignant Pancreatic Neoplasm	The Third Xiangya Hospital of Central South University	Early P1	NR ()
Xer-001 Malignant Pancreatic Neoplasm	Xerient Pharma	P1/2	NR ()

Showing 301 to 314 of 314 assets

PreviousPage 7 of 7Next